Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting
Authors
Keywords
-
Journal
Nature Reviews Neurology
Volume 14, Issue 2, Pages 75-93
Publisher
Springer Nature
Online
2018-01-12
DOI
10.1038/nrneurol.2017.171
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
- (2017) Tomas Kalincik et al. LANCET NEUROLOGY
- Gadolinium deposition in the brain: summary of evidence and recommendations
- (2017) Vikas Gulani et al. LANCET NEUROLOGY
- Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
- (2017) Johannes Lorscheider et al. NEUROLOGY
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis
- (2017) Michael G. Dwyer et al. NeuroImage-Clinical
- Dynamic Imaging of Individual Remyelination Profiles in Multiple Sclerosis
- (2016) Benedetta Bodini et al. ANNALS OF NEUROLOGY
- Neuroinflammatory component of gray matter pathology in multiple sclerosis
- (2016) Elena Herranz et al. ANNALS OF NEUROLOGY
- Long-term evolution of multiple sclerosis disability in the treatment era
- (2016) et al. ANNALS OF NEUROLOGY
- In vivo dentate nucleus MRI relaxometry correlates with previous administration of Gadolinium-based contrast agents
- (2016) Enrico Tedeschi et al. EUROPEAN RADIOLOGY
- Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics
- (2016) Angela Vidal-Jordana et al. JOURNAL OF NEUROIMAGING
- Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study
- (2016) Caryl J. Schwartzbach et al. JOURNAL OF NEUROLOGY
- LEVODOPA-INDUCED DYSKINESIA IN PARKINSON'S: A LONGITUDINAL PET STUDY
- (2016) Andreas-Antonios Roussakis et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial
- (2016) Harold L Atkins et al. LANCET
- Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial
- (2016) Rhian Raftopoulos et al. LANCET NEUROLOGY
- Gadolinium deposition in the brain
- (2016) Tomonori Kanda et al. MAGNETIC RESONANCE IMAGING
- No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing–remitting multiple sclerosis (the ARIANNA study)
- (2016) Roberta Lanzillo et al. Multiple Sclerosis Journal
- Brain atrophy measurements should be used to guide therapy monitoring in MS – Commentary
- (2016) Declan Chard Multiple Sclerosis Journal
- Brain atrophy measurements should be used to guide therapy monitoring in MS – YES
- (2016) Robert Zivadinov et al. Multiple Sclerosis Journal
- Brain atrophy measurements should be used to guide therapy monitoring in MS – NO
- (2016) Frederik Barkhof Multiple Sclerosis Journal
- Slowly eroding lesions in multiple sclerosis
- (2016) Varun Sethi et al. Multiple Sclerosis Journal
- MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
- (2016) Ayman Tourbah et al. Multiple Sclerosis Journal
- NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs
- (2016) Maria Pia Sormani et al. Multiple Sclerosis Journal
- Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome
- (2016) WJ Brownlee et al. Multiple Sclerosis Journal
- Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
- (2016) Ludwig Kappos et al. Multiple Sclerosis Journal
- Assessing response to interferon-β in a multicenter dataset of patients with MS
- (2016) Maria Pia Sormani et al. NEUROLOGY
- Lesion filling effect in regional brain volume estimations: a study in multiple sclerosis patients with low lesion load
- (2016) D Pareto et al. NEURORADIOLOGY
- Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders
- (2016) Yara Dadalti Fragoso et al. NEUROREHABILITATION
- No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing–remitting multiple sclerosis (the ARIANNA study)
- (2016) Roberta Lanzillo et al. Multiple Sclerosis Journal
- Brain atrophy measurements should be used to guide therapy monitoring in MS – Commentary
- (2016) Declan Chard Multiple Sclerosis Journal
- Brain atrophy measurements should be used to guide therapy monitoring in MS – YES
- (2016) Robert Zivadinov et al. Multiple Sclerosis Journal
- Brain atrophy measurements should be used to guide therapy monitoring in MS – NO
- (2016) Frederik Barkhof Multiple Sclerosis Journal
- Slowly eroding lesions in multiple sclerosis
- (2016) Varun Sethi et al. Multiple Sclerosis Journal
- MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
- (2016) Ayman Tourbah et al. Multiple Sclerosis Journal
- NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs
- (2016) Maria Pia Sormani et al. Multiple Sclerosis Journal
- Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome
- (2016) WJ Brownlee et al. Multiple Sclerosis Journal
- Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
- (2016) Ludwig Kappos et al. Multiple Sclerosis Journal
- Reliable measurements of brain atrophy in individual patients with multiple sclerosis
- (2016) Dirk Smeets et al. Brain and Behavior
- Precision Medicine in Multiple Sclerosis: Future of PET Imaging of Inflammation and Reactive Astrocytes
- (2016) Pekka Poutiainen et al. Frontiers in Molecular Neuroscience
- Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis
- (2015) A. Traboulsee et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study
- (2015) Shiv Saidha et al. ANNALS OF NEUROLOGY
- Defining reliable disability outcomes in multiple sclerosis
- (2015) Tomas Kalincik et al. BRAIN
- Defining high, medium and low impact prognostic factors for developing multiple sclerosis
- (2015) Mar Tintore et al. BRAIN
- Treating relapsing–remitting multiple sclerosis: therapy effects on brain atrophy
- (2015) Angela Vidal-Jordana et al. JOURNAL OF NEUROLOGY
- ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis
- (2015) Robert C. Sergott et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process
- (2015) Àlex Rovira et al. Nature Reviews Neurology
- Diurnal fluctuations in brain volume: Statistical analyses of MRI from large populations
- (2015) Kunio Nakamura et al. NEUROIMAGE
- Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
- (2015) D. H. Miller et al. NEUROLOGY
- Can leptomeningeal enhancement be linked to multiple sclerosis?
- (2015) F. Barkhof et al. NEUROLOGY
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2015) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial
- (2015) Claire M. Rice et al. Trials
- Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis
- (2015) Jeffrey Cohen et al. JAMA Neurology
- High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS)
- (2015) Richard A. Nash et al. JAMA Neurology
- Magnetic resonance outcome measures in multiple sclerosis trials
- (2014) Massimo Filippi et al. CURRENT OPINION IN NEUROLOGY
- Clinical Trials to Clinical Use
- (2014) Laura J. Balcer JOURNAL OF NEURO-OPHTHALMOLOGY
- Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study
- (2014) Douglas L. Arnold et al. JOURNAL OF NEUROLOGY
- A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
- (2014) T. L. Vollmer et al. JOURNAL OF NEUROLOGY
- Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience
- (2014) Joachim Burman et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis
- (2014) Carsten Lukas et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial
- (2014) Jeremy Chataway et al. LANCET
- Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Aaron E Miller et al. LANCET NEUROLOGY
- Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial
- (2014) Thomas P Leist et al. LANCET NEUROLOGY
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Composite end points to assess delay of disability progression by MS treatments
- (2014) J Zhang et al. Multiple Sclerosis Journal
- Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes
- (2014) Raquel Mitjana et al. Multiple Sclerosis Journal
- Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial
- (2014) Luca Massacesi et al. PLoS One
- Fluoxetine in Progressive Multiple Sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial
- (2014) Melissa Cambron et al. Trials
- Disease Activity Free Status
- (2014) Carolyn J. Bevan et al. JAMA Neurology
- Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
- (2013) Omar Khan et al. ANNALS OF NEUROLOGY
- Randomized study combining interferon and glatiramer acetate in multiple sclerosis
- (2013) Fred D. Lublin et al. ANNALS OF NEUROLOGY
- Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis
- (2013) Maria Pia Sormani et al. ANNALS OF NEUROLOGY
- Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis
- (2013) Yvonne C Learmonth et al. BMC Neurology
- Sodium accumulation is associated with disability and a progressive course in multiple sclerosis
- (2013) David Paling et al. BRAIN
- Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial
- (2013) John Zajicek et al. LANCET NEUROLOGY
- MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
- (2013) Maria Pia Sormani et al. LANCET NEUROLOGY
- Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis
- (2013) Judith M Sonder et al. Multiple Sclerosis Journal
- Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes
- (2013) Angela Vidal-Jordana et al. Multiple Sclerosis Journal
- Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
- (2013) Patrick Vermersch et al. Multiple Sclerosis Journal
- Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy
- (2013) L. Horton et al. NEUROLOGY
- Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis
- (2013) Marco A. Zarbin et al. OPHTHALMOLOGY
- Dangers of non-specific composite outcome measures in clinical trials
- (2013) D. Prieto-Merino et al. BMJ-British Medical Journal
- Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis
- (2012) H. Vrenken et al. JOURNAL OF NEUROLOGY
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS
- (2012) Robert J Fox et al. Multiple Sclerosis Journal
- NODDI: Practical in vivo neurite orientation dispersion and density imaging of the human brain
- (2012) Hui Zhang et al. NEUROIMAGE
- Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
- (2012) Giancarlo Comi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
- (2011) Chris H. Polman et al. ANNALS OF NEUROLOGY
- Paced auditory serial addition test (PASAT): a very difficult test even for individuals with high intellectual capability
- (2011) Joseph Bruno Bidin Brooks et al. ARQUIVOS DE NEURO-PSIQUIATRIA
- The changing face of multiple sclerosis clinical trial populations
- (2011) Bernard M.J. Uitdehaag et al. CURRENT MEDICAL RESEARCH AND OPINION
- A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
- (2011) A. Novotna et al. EUROPEAN JOURNAL OF NEUROLOGY
- Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial
- (2011) Per Soelberg Sorensen et al. LANCET NEUROLOGY
- Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial
- (2011) Giancarlo Comi et al. LANCET NEUROLOGY
- Grey matter damage and overall cognitive impairment in primary progressive multiple sclerosis
- (2011) C Tur et al. Multiple Sclerosis Journal
- Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
- (2011) DW Langdon et al. Multiple Sclerosis Journal
- MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials
- (2011) Frederik Barkhof et al. Nature Reviews Neurology
- Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis
- (2011) M. P. Sormani et al. NEUROLOGY
- A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS
- (2011) M. S. Freedman et al. NEUROLOGY
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III dose-comparison study of glatiramer acetate for multiple sclerosis
- (2010) Giancarlo Comi et al. ANNALS OF NEUROLOGY
- Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial
- (2010) Raju Kapoor et al. LANCET NEUROLOGY
- Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?
- (2010) LVAE Bosma et al. Multiple Sclerosis Journal
- Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
- (2010) N. De Stefano et al. NEUROLOGY
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
- (2010) Gavin Giovannoni et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fatigue Impact Scale
- (2010) J. Frith et al. OCCUPATIONAL MEDICINE-OXFORD
- Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach
- (2009) Maria Pia Sormani et al. ANNALS OF NEUROLOGY
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
- (2009) G Comi et al. LANCET
- Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
- (2009) Andrew D Goodman et al. LANCET
- 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
- (2009) Paul O'Connor et al. LANCET NEUROLOGY
- A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
- (2009) X. Montalban et al. Multiple Sclerosis Journal
- The development of patient-reported outcome indices for multiple sclerosis (PRIMUS)
- (2009) LC Doward et al. Multiple Sclerosis Journal
- Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?
- (2009) R. Pelayo et al. Multiple Sclerosis Journal
- Predicting responders to therapies for multiple sclerosis
- (2009) Jordi Río et al. Nature Reviews Neurology
- Gray matter atrophy in multiple sclerosis: A longitudinal study
- (2008) Elizabeth Fisher et al. ANNALS OF NEUROLOGY
- Gray matter atrophy is related to long-term disability in multiple sclerosis
- (2008) Leonora K. Fisniku et al. ANNALS OF NEUROLOGY
- Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
- (2008) Bruce D. Trapp et al. Annual Review of Neuroscience
- Multiple sclerosis
- (2008) Alastair Compston et al. LANCET
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
- (2008) Daniel D Mikol et al. LANCET NEUROLOGY
- Multimodal evoked potentials measure and predict disability progression in early relapsing–remitting multiple sclerosis
- (2008) P Jung et al. Multiple Sclerosis Journal
- Disability as an outcome in MS clinical trials
- (2008) G. C. Ebers et al. NEUROLOGY
- Responsiveness and predictive value of EDSS and MSFC in primary progressive MS
- (2008) J. J. Kragt et al. NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now